Author

S. Short

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Organism:mouse· 3 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Research Focus:host-pathogen & immune response· 2

Frequent Co-Authors

A. Brodbelt· 1 shared A. Bruning-Richardson· 1 shared A. Chakrabarty· 1 shared A. Droop· 1 shared A. F. Bruns· 1 shared A. Gusnanto· 1 shared A. Ismail· 1 shared A. Kwag· 1 shared

Activity by Year

2022-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Brodbelt

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

LRRK2 G2019S promotes the development of colon cancer via modulating intestinal inflammation

Z. Kang, Y. Wang, J. Z. Gao, T. Sakaguchi, T. Maretzky, P. Gurung, S. Short, Y. Xiong

This study shows that LRRK2 G2019S promotes colon cancer by enhancing intestinal inflammation and tumor growth in mice.

bioRxiv · Jun 28, 2023Immunology

Eosinophils exert direct and indirect anti-tumorigenic effects in the development of esophageal squamous cell carcinoma

J. Jacobse, Z. Aziz, L. Sun, J. Chaparro, J. M. Pilat, A. Kwag, M. Buendia, M. Wimbiscus, M. Nasu, T. Saito, S. Mine, H. Orita, F. Revetta, S. Short, M. K. Washington, , Y. A. Choksi

This study shows eosinophils reduce esophageal squamous cell carcinoma by releasing reactive oxygen species and inhibiting IL-17 pathways.

bioRxiv · Jun 1, 2023 · PreprintCancer Biology

Multi-omic Profiling Reveals Early Immunological Indicators for Identifying COVID-19 Progressors

K. A. Drake, D. Talantov, G. Tong, J. T. Lin, S. Verheijden, S. Katz, J. M. Leung, B. Yuen, V. Krishna, M. J. Wu, A. Sutherland, S. Short, P. Kheradpour, M. R. Mumbach, K. M. Franz, , The PRESCO Study Group

The paper identifies early immunological indicators of severe COVID-19 by analyzing multi-omic data from the immediate post-diagnosis phase.

bioRxiv · May 25, 2023Immunology

IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy

G. Tanner, R. Barrow, M. Finetti, S. Ajaib, N. Ahmed, S. Pollock, N. Rippaus, A. F. Bruns, K. Syed, J. Poulter, E. A. Wilson, C. A. Johnson, F. S. Varn, A. Bruning-Richardson, C. Hogg, , L. F. Stead

This study identifies two IDHwt glioblastoma subtypes based on transcriptional response to treatment, with distinct resistance mechanisms and potential therapeutic implications.

bioRxiv · Feb 3, 2023Cancer Biology

The m6A reader IGF2BP2 directs immune-metabolic reprogramming in Leishmania amazonensis-infected macrophages

S. Zhang, H. Lecoeur, H. Varet, R. Legendre, N. Mahtal, C. Proux, N. Aulner, S. Short, C. Grandjean, P. Bousso, E. Prina, G. F. Spaeth

This study identifies IGF2BP2 as an m6A reader that stabilizes glycolytic transcripts in Leishmania-infected macrophages, promoting HIF-1-independent glycolysis and immune-metabolic reprogramming.

bioRxiv · Sep 8, 2022 · PreprintImmunology